WO2014170900A1 - Inhibiteurs du récepteur eph-a et utilisations de ces derniers - Google Patents

Inhibiteurs du récepteur eph-a et utilisations de ces derniers Download PDF

Info

Publication number
WO2014170900A1
WO2014170900A1 PCT/IL2014/050359 IL2014050359W WO2014170900A1 WO 2014170900 A1 WO2014170900 A1 WO 2014170900A1 IL 2014050359 W IL2014050359 W IL 2014050359W WO 2014170900 A1 WO2014170900 A1 WO 2014170900A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
seq
peptide according
acid sequence
Prior art date
Application number
PCT/IL2014/050359
Other languages
English (en)
Inventor
Raphael LEMPRECHT
Monica DINES
Original Assignee
University Of Haifa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Haifa filed Critical University Of Haifa
Priority to EP14785453.3A priority Critical patent/EP2986627B1/fr
Priority to US14/785,456 priority patent/US9765116B2/en
Publication of WO2014170900A1 publication Critical patent/WO2014170900A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Embodiments of the invention relate to inhibitors of the EphA receptor and methods of treating disease using the inhibitors.
  • Eph receptors are a group of transmembrane receptors found in human and animal cells from the family of receptor tyrosine kinases. Eph receptors identify intercellular interactions by transmitting signals into cells in which they are located following binding to their corresponding ephrin ligands, transmembranal ligands generally attached to an opposing cell surface.
  • Ephs may be divided into two general classes: EphA and EphB. Humans express nine EphAs and five EphBs. Generally, Ephs of specific class preferentially bind ephrins of the corresponding class. However, there are exceptions to this, for example, binding of EphA4 by ephrin-B3 and ephrin-B2.
  • Eph-ephrin interactions mediate many cell-cell interactions in the human body including interactions relating to embryo formation, memory formation, neuron formation and cancer.
  • EphA4 an inhibitory peptide specific to EphA receptor, particularly EphA4, effective in treating EphA related disease, and particularly in humans, including but not limited to post-traumatic stress disorder (PTSD).
  • PTSD post-traumatic stress disorder
  • the present invention provides peptides derived from the G-H loop of ephrin A4, and pharmaceutical compositions comprising same effective in treating or ameliorating diseases associated with memory formation.
  • the inventors have synthesized new peptides comprising a sequence of the G-H loop of ephrin A4.
  • the invention is based, in part, on the finding that the peptides are effective in binding to EphA receptors.
  • an exemplary peptide was shown to advantageously bind the EphA4 receptor and inhibit memory formation, thereby indicating that the peptides may be used to treat diseases associated with memory formation in humans, including but not limited to post-traumatic stress disorder (PTSD).
  • PTSD post-traumatic stress disorder
  • an aspect of embodiments of the invention relates to an isolated peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1 (QRX 1 TPFX 2 LGFE), wherein Xi is Tyr (Y) or Phe (F) and X 2 is Pro (P) or Ser (S), or a sequence having a conservative substitution relative to SEQ ID NO: 1.
  • the peptide comprises the amino acid sequence as set forth in SEQ ID NO: 2 (QRYTPFPLGFE). According to another embodiment, the peptide comprises the amino acid sequence as set forth in SEQ ID NO: 3 (QRFTPFSLGFE).
  • the peptide further comprises 1-4 arginine residues contiguous to the peptide's N- terminus.
  • the peptide comprises the amino acid sequence as set forth in SEQ ID NO: 4 (RRQRYTPFPLGFE).
  • the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 4 (RRQRYTPFPLGFE).
  • the peptide comprises the amino acid sequence as set forth in SEQ ID NO: 5 (RRQRFTPFSLGFE).
  • the peptide consists of the amino acid sequence as set forth in SEQ ID NO: 5 (RRQRFTPFSLGFE).
  • the peptide further comprises at least one lysine residue contiguous to the peptide's C- terminus. According to another embodiment, the peptide further comprises one lysine residue contiguous to the peptide's C- terminus. According to some embodiments, the peptide comprises the amino acid sequence as set forth in SEQ ID NO: 6 (QRYTPFPLGFEK). According to some embodiments, the peptide comprises the amino acid sequence as set forth SEQ ID NO: 7 (QRFTPFS LGFEK) .
  • Peptides according to embodiments of the invention may comprise amino acid modifications which comprise natural or synthetic amino acids.
  • Peptides according to embodiments of the invention may comprise amino acid modifications such as acetylation including N-terminal acetylation or amidation. According to a particular embodiment, the N- terminus of said peptide is acetylated.
  • said peptide is an inhibitor of an ephrin type- A (EphA) receptor.
  • said EphA receptor is EphA4 receptor.
  • the pharmaceutical composition is formulated for systemic administration.
  • Systemic administration includes but is not limited to administration modes selected from intravenous administration, subcutaneous administration, inhalation, intradermal administration, transdermal administration, transmucosal administration, and/or oral administration.
  • a method of treating, preventing or alleviating a disease in a subject comprises administering to the subject in need thereof an effective amount of the peptide of the invention or the pharmaceutical composition comprising same.
  • the disease is associated with memory formation.
  • the disease is associated with long-term memory formation.
  • said memory formation is a fear-related memory formation.
  • the disease is selected from the group consisting of post-traumatic stress disorder (PTSD), stress and anxiety.
  • PTSD post-traumatic stress disorder
  • the disease is PTSD.
  • said subject is a mammal, preferably a human.
  • a peptide e.g., SEQ ID NO: 1 of the invention or a pharmaceutical composition comprising same for use in treating, preventing or alleviating a disease in a subject, particularly a disease associated with fear-related memory formation.
  • a peptide of the invention e.g., SEQ ID NO: 1
  • a pharmaceutical composition comprising same for the preparation of a medicament for treating, preventing or alleviating a disease in a subject, particularly a disease associated with fear-related memory formation.
  • Figure 1A shows a graph showing effect of test peptides and saline on long term-memory in rats as determined by percentage of freezing in rats in a fear conditioning model, indicating the ability of peptide 1 injected into the lateral and basal amygdala to inhibit freezing in rats relative to control peptide 2 that do not bind EphA, saline and misplaced peptide 1, which was injected to areas outside of the lateral and basal amygdale.
  • Figure IB shows a graph showing effect of peptide 1 on inhibition of freezing in rats relative to saline, in a Fear Conditioning Model; when both agents were administered systemically.
  • Figure 2 shows a histogram showing strong binding affinity of peptide 1 to
  • EphA4 receptor relative to peptide 2 based on an in vitro pull down model using rat brain homogenate.
  • Figure 3 shows the sequence of Eprhin A4 of rat, mouse and human with the G-H loop underlined.
  • Figure 4 A shows a molecular model of ephrinA4 binding to EphA4 receptor using the Swiss-Model.
  • the control peptide (pep-control) is derived from E helix of the ephrinA4.
  • Figure 4B shows Western blot analysis and a corresponding bar graph of a pull down assay, using the ephrinA4 peptide (pep-ephrinA4) compared to a control peptide (pep-control) or agarose beads alone.
  • Figure 4C shows the results of an immunoprecpitation assay and a corresponding bar graph of the ephrinA4 peptide and the ephrinA4 compared to ephrinA4 and Ringer's solution as controls.
  • the present invention provides in some embodiment EphAs receptor inhibitor peptides, and particularly EphA4 receptor inhibitor peptides.
  • the peptides comprise a sequence derived from the G-H loop of ephrin A4.
  • the invention further provides pharmaceutical compositions comprising said peptides and use thereof in treating, ameliorating or preventing diseases associated with memory formation.
  • peptides e.g., SEQ ID NO: 1
  • SEQ ID NO: 1 comprising a sequence of the G-H loop of ephrin A4 have specific binding affinity to EphA receptor, in particular the EphA4 receptor. Said binding was shown to also result in reduced ephrinA4-induced EphA4 tyrosine phosphorylation ( Figure 4C).
  • an exemplary peptide was demonstrated as capable of inhibiting memory formation, in vivo, thereby indicating use of the peptides in treating diseases associated with memory formation in humans, including but not limited to post-traumatic stress disorder (PTSD).
  • PTSD post-traumatic stress disorder
  • the invention provides an isolated peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1 (QRXiTPFX 2 LGFE), wherein Xi is Tyr (Y) or Phe (F) and X 2 is Pro (P) or Ser (S), or a sequence having a conservative substitution relative to SEQ ID NO: 1.
  • the peptide comprises the amino acid sequence selected from the group consisting of:
  • SEQ ID NO: 5 (RRQRFTPFS LGFE) ;
  • the peptides may be between about 10 and 15 amino acids in length.
  • the peptides may comprise a sequence having between about 8 and about 12 amino acids of the G-H loop of a mammalian (e,g., human, mouse or rat) ephrin A4.
  • the peptide comprises at least 8, at least 9, at least 10, at least 11 amino acids derived from, or corresponds to, the G-H loop of a mammalian ephrin A4.
  • the additional amino acids may be sequences derived from ephrin A4, or may be sequences that are derived from other sources.
  • the peptide retains its inhibitory function when comprising additional arginine residues contiguous to the peptide's N- terminus.
  • the peptide is selected from SEQ ID NO: 4 (RRQRYTPFPLGFE), SEQ ID NO: 5 (RRQRFTPFS LGFE) ; SEQ ID NO: 8 (RRQRYTPFPLGFEK); or SEQ ID NO: 9 (RRQRFTPFS LGFEK).
  • the N- terminus of said peptide is acetylated.
  • the peptide may have a length of no more than 20 amino acids, no more than 19 amino acids, no more than 18 amino acids, no more than 17 amino acids, no more than 16 amino acids, no more than 15 amino acids, no more than 14 amino acids, no more than 13 amino acids or no more than 12 amino acids.
  • the peptide further comprises at least one lysine residue contiguous to the peptide's C- terminus.
  • said peptide is biotinylated via said lysine residue.
  • the EphA receptor inhibitor peptides comprise a sequence derived from the G-H loop of ephrin A4.
  • human epherin A4 may have various isoforms or variants, including but not limited to those of GenBank accession no. CAA06993.1; CAA06992.1; AAI07484.1; NP_872631.1; NP 005218.1; NP_872632.2; EAW53140.1; EAW53139.1; or EAW53138.1.
  • the epherin A4 may be from another source such as murine (Accession no.
  • the human G-H loop of ephrin A4 corresponds to the amino acid sequence QRFTPFSLGFE (SEQ ID NO: 3) of ephrin A4
  • the murine G-H loop of ephrin A4 corresponds to the amino acid sequence QRYTPFPLGFE (SEQ ID NO: 2) of ephrin A4.
  • the peptide is other than the amino acid sequence as set forth in SEQ ID NO: 8 (RFTPFS LGFEFLP) .
  • peptide encompasses native peptides (degradation products, synthetic peptides or recombinant peptides), peptidomimetics (typically including non peptide bonds or other synthetic modifications) and the peptide analogues peptoids and semipeptoids, and may have, for example, modifications rendering the peptides more stable while in the body or more capable of penetrating into cells.
  • polypeptide and “protein” are used interchangeably herein to refer to a polymer of amino acid residues.
  • the terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers.
  • the peptide of the invention comprises a sequence derived from the G-H loop of ephrin A4, with a conservative substitution.
  • a conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has a similar property. Exemplary conservative substitutions are set out in the Table 1 below:
  • the peptide (i.e., the EphA receptor inhibitor peptide) comprises a sequence homologous to a sequence of the G-H loop of ephrin A4.
  • the peptide comprises a sequence having greater 75%, 80%, 85%, 90% or 95% homology to a sequence of the G-H loop of ephrin A4.
  • the peptide comprises a sequence having greater 75%, 80%, 85%, 90% or 95% homology to a sequence of SEQ ID NO: l.
  • the phrase "conservative substitution” also includes the use of a chemically derivatized residue in place of a non-derivatized residue provided that such peptide displays the requisite function of binding to EphA4 receptor and or affecting (e.g., inhibiting) memory formation as specified herein.
  • the present invention encompasses derivatives of the peptides.
  • the term "derivative” or “chemical derivative” includes any chemical derivative of the peptide having one or more residues chemically derivatized by reaction of side chains or functional groups.
  • Such derivatized molecules include, for example, those molecules in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonyl groups, carbobenzoxy groups, t-butyloxycarbonyl groups, chloroacetyl groups or formyl groups.
  • Free carboxyl groups may be derivatized to form salts, methyl and ethyl esters or other types of esters or hydrazides.
  • Free hydroxyl groups may be derivatized to form O-acyl or O-alkyl derivatives.
  • the imidazole nitrogen of histidine may be derivatized to form N-im-benzylhistidine.
  • chemical derivatives are those peptides, which contain one or more naturally occurring amino acid derivatives of the twenty standard amino acid residues. For example: 4-hydroxyproline may be substituted for proline; 5-hydroxylysine may be substituted for lysine; 3-methylhistidine may be substituted for histidine; homoserine may be substituted or serine; and ornithine may be substituted for lysine.
  • a peptide derivative can differ from the natural sequence of the peptides of the invention by chemical modifications including, but are not limited to, terminal-NH2 acylation, acetylation, or thioglycolic acid amidation, and by terminal-carboxlyamidation, e.g., with ammonia, methylamine, and the like.
  • Peptides can be either linear, cyclic or branched and the like, which conformations can be achieved using methods well known in the art.
  • the present invention also encompasses peptide derivatives and analogs in which free amino groups have been derivatized to form amine hydrochlorides, p-toluene sulfonylamino groups, carbobenzoxyamino groups, t-butyloxycarbonylamino groups, chloroacetylamino groups or formylamino groups.
  • Free carboxyl groups may be derivatized to form, for example, salts, methyl and ethyl esters or other types of esters or hydrazides.
  • the imidazole nitrogen of histidine can be derivatized to form N-im-benzylhistidine.
  • the peptide analogs can also contain non-natural amino acids.
  • non-natural amino acids include, but are not limited to, sarcosine (Sar), norleucine, ornithine, citrulline, diaminobutyric acid, homoserine, isopropyl Lys, 3-(2'-naphtyl)-Ala, nicotinyl Lys, amino isobutyric acid, and 3-(3'-pyridyl-Ala).
  • the peptide analogs can contain other derivatized amino acid residues including, but not limited to, methylated amino acids, N-benzylated amino acids, O-benzylated amino acids, N-acetylated amino acids, O-acetylated amino acids, carbobenzoxy-substituted amino acids and the like.
  • Specific examples include, but are not limited to, methyl- Ala (Me Ala), MeTyr, MeArg, MeGlu, MeVal, MeHis, N-acetyl-Lys, O-acetyl-Lys, carbobenzoxy-Lys, Tyr-O-Benzyl, Glu-O-Benzyl, Benzyl-His, Arg-Tosyl, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, and the like.
  • the invention further includes peptide analogs, which can contain one or more
  • D-isomer forms of the amino acids are D-isomer forms of the amino acids.
  • Production of retro-inverso D-amino acid peptides where at least one amino acid, and perhaps all amino acids are D-amino acids is well known in the art.
  • all of the amino acids in the peptide are D-amino acids, and the N- and C-terminals of the molecule are reversed, the result is a molecule having the same structural groups being at the same positions as in the L-amino acid form of the molecule.
  • the molecule is more stable to proteolytic degradation and is therefore useful in many of the applications recited herein.
  • Diastereomeric peptides may be highly advantageous over all L- or all D-amino acid peptides having the same amino acid sequence because of their higher water solubility, lower immunogenicity, and lower susceptibility to proteolytic degradation.
  • the term "diastereomeric peptide" as used herein refers to a peptide comprising both L-amino acid residues and D-amino acid residues.
  • the number and position of D-amino acid residues in a diastereomeric peptide of the preset invention may be variable so long as the peptide is capable of displaying the requisite function of binding to EphA4 receptor and or affecting (e.g., inhibiting) memory formation as specified herein.
  • salts refers to both salts of carboxyl groups and to acid addition salts of amino or guanido groups of the peptide molecule.
  • Salts of carboxyl groups may be formed by means known in the art and include inorganic salts, for example sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases such as salts formed for example with amines such as triethanolamine, piperidine, procaine, and the like.
  • Acid addition salts include, for example, salts with mineral acids such as, for example, acetic acid or oxalic acid. Salts describe here also ionic components added to the peptide solution to enhance hydrogel formation and /or mineralization of calcium minerals.
  • the peptides of the invention may be synthesized or prepared by techniques well known in the art.
  • the peptides can be synthesized by a solid phase peptide synthesis method of Merrifield (see J. Am. Chem. Soc, 85:2149, 1964).
  • the peptides of the present invention can be synthesized using standard solution methods well known in the art (see, for example, Bodanszky, M., Principles of Peptide Synthesis, Springer- Verlag, 1984) or by any other method known in the art for peptide synthesis.
  • these methods comprise sequential addition of one or more amino acids or suitably protected amino acids to a growing peptide chain bound to a suitable resin.
  • either the amino or carboxyl group of the first amino acid is protected by a suitable protecting group.
  • the protected or derivatized amino acid can then be either attached to an inert solid support (resin) or utilized in solution by adding the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected, under conditions conductive for forming the amide linkage.
  • the protecting group is then removed from this newly added amino acid residue and the next amino acid (suitably protected) is added, and so forth.
  • any remaining protecting groups are removed sequentially or concurrently, and the peptide chain, if synthesized by the solid phase method, is cleaved from the solid support to afford the final peptide.
  • the alpha-amino group of the amino acid is protected by an acid or base sensitive group.
  • Such protecting groups should have the properties of being stable to the conditions of peptide linkage formation, while being readily removable without destruction of the growing peptide chain.
  • Suitable protecting groups are t-butyloxycarbonyl (BOC), benzyloxycarbonyl (Cbz), biphenylisopropyloxycarbonyl, t-amyloxycarbonyl, isobornyloxycarbonyl, (alpha,alpha)-dimethyl-3 ,5 dimethoxybenzyloxycarbonyl, o-nitrophenylsulfenyl, 2-cyano-t-butyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC) and the like.
  • BOC t-butyloxycarbonyl
  • Cbz benzyloxycarbonyl
  • biphenylisopropyloxycarbonyl t-amyloxycarbonyl
  • isobornyloxycarbonyl (alpha,alpha)-dimethyl-3 ,5 dimethoxybenzyloxycarbonyl
  • o-nitrophenylsulfenyl 2-cyano-t-buty
  • the C-terminal amino acid is attached to a suitable solid support.
  • suitable solid supports useful for the above synthesis are those materials, which are inert to the reagents and reaction conditions of the stepwise condensation-deprotection reactions, as well as being insoluble in the solvent media used.
  • Suitable solid supports are chloromethylpolystyrene-divinylbenzene polymer, hydroxymethyl-polystyrene-divinylbenzene polymer, and the like.
  • the coupling reaction is accomplished in a solvent such as ethanol, acetonitrile, ⁇ , ⁇ -dimethylformamide (DMF), and the like.
  • the coupling of successive protected amino acids can be carried out in an automatic polypeptide synthesizer as is well known in the art.
  • the peptides of the invention may alternatively be synthesized such that one or more of the bonds, which link the amino acid residues of the peptides are non-peptide bonds.
  • bonds include, but are not limited to, imino, ester, hydrazide, semicarbazide, and azo bonds, which can be formed by reactions well known to skilled in the art.
  • the peptides of the present invention, analogs or derivatives thereof produced by recombinant techniques can be purified so that the peptides will be substantially pure when administered to a subject.
  • substantially pure refers to a compound, e.g., a peptide, which has been separated from components, which naturally accompany it.
  • a peptide is substantially pure when at least 50%, preferably at least
  • peptide of interest 75%, more preferably at least 90%, and most preferably at least 99% of the total material (by volume, by wet or dry weight, or by mole percent or mole fraction) in a sample is the peptide of interest. Purity can be measured by any appropriate method, e.g., in the case of peptides by HPLC analysis.
  • peptide conjugates comprising the peptides of the present invention derivatives or analogs thereof joined at their amino or carboxy-terminus or at one of the side chains via a peptide bond to an amino acid sequence of a different protein.
  • Conjugates comprising peptides of the invention and a protein can be made by protein synthesis, e. g., by use of a peptide synthesizer, or by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the conjugate by methods commonly known in the art.
  • Addition of amino acid residues may be performed at either terminus of the peptides of the invention for the purpose of providing a "linker" by which the peptides of this invention can be conveniently bound to a carrier.
  • linkers are usually of at least one amino acid residue and can be of 40 or more residues, more often of 1 to 10 residues.
  • Typical amino acid residues used for linking are tyrosine, cysteine, lysine, glutamic and aspartic acid, or the like.
  • the EphA receptor inhibitor peptide is conjugated to an agent which modulates the peptide's biological activity.
  • the agent which modulates the peptide's biological activity is an agent designed to increase the half-life of the peptide in the bloodstream, for example polyethylene glycol.
  • the agent which modulates the peptide's biological activity enhances penetration of the blood-brain barrier by the peptide, for example, an agent having a lipophilic moiety.
  • the EphA receptor inhibitor peptide is conjugated to an agent which allows for the binding or detection of the peptide.
  • the agent which allows for the binding or detection of the peptide is bio tin.
  • the peptide of the invention has increased selectively to EphA receptor, particularly to EphA4 receptor. In some embodiments, the peptide of the invention has substantially greater selectively to EphA4 receptor as compared to other Eph receptors.
  • selectively is meant having a binding affinity for one or a few Eph receptor family members that is substantially greater than said binding affinity for the other known Eph receptor family members.
  • substantially greater means at least a two-fold, at least a three-fold, at least a four-fold, at least a five-fold, at least a six fold, at least a seven-fold, at least a eight-fold, at least a nine-fold, at least a ten-fold, at least a fifteen-fold, at least a twenty-fold, at least a thirty-fold, at least a forty-fold, at least a fifty-fold or at least a hundred-fold increase in the amount of peptide bound to a receptor.
  • compositions of the invention comprising as an active ingredient a therapeutically effective amount of a peptide of the present invention (e.g., SEQ ID NO: 1), and a pharmaceutically acceptable carrier.
  • compositions of the invention can be formulated in the form of a pharmaceutically acceptable salt of the peptides of the present invention or their analogs, or derivatives thereof.
  • Pharmaceutically acceptable salts include those salts formed with free amino groups such as salts derived from non-toxic inorganic or organic acids such as hydrochloric, phosphoric, acetic, oxalic, tartaric acids, and the like, and those salts formed with free carboxyl groups such as salts derived from non- toxic inorganic or organic bases such as sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • pharmaceutically acceptable means suitable for administration to a subject, e.g., a human.
  • pharmaceutically acceptable can mean approved by a regulatory agency of the Federal or a state government or listed in the U. S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic compound is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol and the like.
  • the composition can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents such as acetates, citrates or phosphates.
  • Antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; and agents for the adjustment of tonicity such as sodium chloride or dextrose are also envisioned.
  • compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, gels, creams, ointments, foams, pastes, sustained-release formulations and the like.
  • the compositions can be formulated as a suppository, with traditional binders and carriers such as triglycerides, microcrystalline cellulose, gum tragacanth or gelatin.
  • Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in: Remington's Pharmaceutical Sciences" by E.W. Martin, the contents of which are hereby incorporated by reference herein.
  • Such compositions will contain a therapeutically effective amount of the peptide of the invention, preferably in a substantially purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the subject.
  • An embodiment of the invention relates to a peptide presented in unit dosage form and are prepared by any of the methods well known in the art of pharmacy.
  • the unit dosage form is in the form of a tablet, capsule, lozenge, wafer, patch, ampoule, vial or pre-filled syringe.
  • in vitro assays may optionally be employed to help identify optimal dosage ranges.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the nature of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses can be extrapolated from dose-response curves derived from in-vitro or in-vivo animal model test bioassays or systems.
  • the peptides of the present invention can be supplied in any manner suitable for the provision of the peptide to cells within the tissue of interest.
  • a composition containing the peptides of the present invention can be introduced, for example, into the systemic circulation, which will distribute said peptide to the tissue of interest.
  • a composition can be applied topically to the tissue of interest (e.g., injected, or pumped as a continuous infusion, or as a bolus within a tissue, applied to all or a portion of the surface of the skin, etc.).
  • peptides are administered via oral, rectal, vaginal, topical, nasal, ophthalmic, transdermal, subcutaneous, intramuscular, intraperitoneal or intravenous routes of administration.
  • the route of administration of the pharmaceutical composition will depend on the disease or condition to be treated. Suitable routes of administration include, but are not limited to, parenteral injections, e.g., intradermal, intravenous, intramuscular, intralesional, subcutaneous, intrathecal, and any other mode of injection as known in the art.
  • compositions of the invention can be lower than when administered via parenteral injection, by using appropriate formulations it is envisaged that it will be possible to administer the compositions of the invention via transdermal, oral, rectal, vaginal, topical, nasal, inhalation and ocular modes of treatment.
  • Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer.
  • a peptide of the present invention, derivative, analog or a fragment thereof can be combined with a pharmaceutically acceptable carrier so that an effective dosage is delivered, based on the desired activity.
  • the carrier can be in the form of, for example, and not by way of limitation, an ointment, cream, gel, paste, foam, aerosol, suppository, pad or gelled stick.
  • the pharmaceutical composition may be in the form of tablets or capsules, which can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; or a glidant such as colloidal silicon dioxide.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose
  • a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide.
  • dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier such as fatty oil.
  • dosage unit forms can contain various other materials which modify the physical form
  • solutions in sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions of the corresponding water-soluble salts.
  • aqueous solutions may be suitably buffered, if necessary, and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal injection purposes.
  • compositions of the present invention are generally administered in the form of a pharmaceutical composition comprising at least one of the active components of this invention together with a pharmaceutically acceptable carrier or diluent.
  • the compositions of this invention can be administered either individually or together in any conventional oral, parenteral or transdermal dosage form.
  • Pharmaceutical compositions according to embodiments of the invention may contain 0.1%-95% of the active components(s) of this invention, preferably l%-70%.
  • the composition or formulation to be administered may contain a quantity of active components according to embodiments of the invention in an amount effective to treat the condition or disease of the subject being treated.
  • the daily dosage of the peptide is between 0.1 mg and 1500 mg.
  • the peptides of the present invention, derivatives, or analogs thereof can be delivered in a controlled release system.
  • an infusion pump can be used to administer the peptide such as the one that is used, for example, for delivering insulin or chemotherapy to specific organs or tumors.
  • the peptide of the invention is administered in combination with a biodegradable, biocompatible polymeric implant, which releases the peptide over a controlled period of time at a selected site.
  • polymeric materials include, but are not limited to, polyanhydrides, polyorthoesters, polyglycolic acid, polylactic acid, polyethylene vinyl acetate, copolymers and blends thereof (See, Medical applications of controlled release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla., the contents of which are hereby incorporated by reference in their entirety).
  • a controlled release system can be placed in proximity to a therapeutic target, thus requiring only a fraction of the systemic dose.
  • peptides of the invention are EphA4 antagonists.
  • antagonist refers to a biologically active ligand which binds to its complementary biologically active receptor and inhibits the physiological response of the receptor.
  • the peptides and composition of the invention are useful for treating or ameliorating affective disorders, particularly anxiety disorders.
  • affective disorders or “mood disorders” as used herein, relate to a set of psychiatric diseases, including depression, bipolar disorder, and anxiety disorder.
  • Anxiety disorders are characterized by feelings of nervousness, anxiety, and even fear. They are several types of anxiety disorders, including: social anxiety (i.e., anxiety caused by social situations); post-traumatic stress disorder (PTSD, i.e., anxiety, fear, and flashbacks caused by a traumatic event); generalized anxiety disorder (i.e., anxiousness and fear in general, with no particular cause); panic disorder (i.e., anxiety that causes panic attacks); and obsessive-compulsive disorder (i.e., obsessive thoughts that cause anxiety and compulsive actions.
  • social anxiety i.e., anxiety caused by social situations
  • PTSD post-traumatic stress disorder
  • generalized anxiety disorder i.e., anxiousness and fear in general, with no particular cause
  • panic disorder i.e., anxiety that causes panic attacks
  • obsessive-compulsive disorder i.e., obsessive thoughts that cause anxiety and compulsive actions.
  • Depression or major depressive disorder, is characterized by feelings of extreme sadness and hopelessness, with experience episodes that last for several days or even weeks.
  • a milder form of depression is called dysthymia.
  • Bipolar disorder means having periods of depression, and periods of mania, i.e., periods of the subject feeling extremely positive and active, resulting in irritable, aggressive, impulsive, and even delusional behavior.
  • Non limiting examples of affective disorders include, but are not limited to anxiety disorders (e.g., generalized anxiety disorder (GAD), social anxiety disorder (SAD; alternatively known as social phobia), panic disorder (with or without agoraphobia), posttraumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), separation anxiety disorder), mood disorders (e.g., depressive disorder, bipolar disorder) and psychotic disorders (e.g., schizophrenia, schizoaffective disorder, delusional disorder), substance-related disorders (e.g., substance abuse, substance-induced disorder, substance withdrawal).
  • GAD generalized anxiety disorder
  • SAD social anxiety disorder
  • PTSD posttraumatic stress disorder
  • OCD obsessive-compulsive disorder
  • separation anxiety disorders e.g., depression disorder, bipolar disorder
  • mood disorders e.g., depressive disorder, bipolar disorder
  • psychotic disorders e.g., schizophrenia, schizoaffective disorder, delusional disorder
  • substance-related disorders e.g.,
  • the present invention provides methods of treating a psychiatric condition selected from a neuropsychiatric disorder, an affective disorder, depression, hypomania, panic attacks, anxiety, excessive elation, bipolar depression, bipolar disorder (manic-depression), seasonal mood (or affective) disorder, schizophrenia and other psychoses, anxiety syndromes, anxiety disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behavior syndromes, borderline personality disorder, non-senile dementia, post-pain depression, post-partum depression, cerebral palsy, post-traumatic stress disorder (PTSD), and combinations thereof.
  • a psychiatric condition selected from a neuropsychiatric disorder, an affective disorder, depression, hypomania, panic attacks, anxiety, excessive elation, bipolar depression, bipolar disorder (manic-depression), seasonal mood (or affective) disorder, schizophrenia and other psychoses, anxiety syndromes, anxiety disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse
  • the present invention provides a method of treating disorders characterized by aversive, unwanted, disturbing, traumatic, fearful, intrusive, repetitive or stereotyped memories, thoughts, perceptions or behaviors, comprising administering to a patient in need thereof a therapeutically effective amount of a peptide or composition of the invention. Furthermore the invention relates to the use of said peptides for such a treatment, and to the use of said peptides for the manufacture of a medicament for the treatment of the mentioned disorders.
  • disorders include, but are not limited to, phobias, posttraumatic stress disorder and obsessive-compulsive disorder.
  • Phobias are characterized by marked and persistent fear that is excessive or unreasonable, cued by the presence or anticipation of a specific object or situation (e.g., flying, heights, animals, receiving an injection, seeing blood, social, performance). Exposure to the phobic stimulus almost invariably provokes retrieval of stimulus- associated fearful memories, which results in an immediate anxiety response. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational functioning, or social activities or relationships, or there is marked distress about having the phobia.
  • a specific object or situation e.g., flying, heights, animals, receiving an injection, seeing blood, social, performance.
  • phobias The defining criteria for a diagnosis of phobias can be found in the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV), published by the American Psychiatric Association, Washington D.C., 1994.
  • Psychological treatment options of phobias include desensitization and exposure (for specific phobias) and cognitive behavioral therapy (for social phobias).
  • Pharmacological treatment options include beta-blockers, selective serotonin reuptake inhibitors and monoamine oxidase inhibitors.
  • Obsessive-Compulsive Disorder is an anxiety disorder characterized by recurrent obsessions or compulsions sufficient to cause marked distress. These behaviors are time-consuming, or significantly interfere with the person's normal functioning, social activities or relationships. Obsessions are recurrent ideas, thoughts, images, or impulses that enter the mind and are persistent, intrusive, and unwelcome. Compulsions are repetitive, purposeful behaviors performed in response to an obsession, and are designed to neutralize or prevent discomfort or some dreaded event or situation. However, the activity is excessive, or not connected realistically with that which it is designed to prevent. The defining criteria for a diagnosis of OCD are well known to a skilled artisan. Psychological treatment options of OCD include cognitive-behavioral techniques. Pharmacological treatment options include serotonin reuptake inhibitors. However, not all patients with OCD respond to serotonin reuptake inhibitors, some do not tolerate them, and many have only a partial response.
  • Post-traumatic stress disorder is a debilitating psychiatric disorder induced by exposure to a severe trauma and is typically associated with functional impairments and increased physical and mental health risks. PTSD patients tend to have a six fold higher risk of suicide than non-PTSD patients.
  • the treatment of PTSD is challenging, and may include many years of individual and group therapy and treatment with medications such as antidepressants, anxiolytic drugs, ⁇ -adrenergic antagonists, opiates, or Cortisol with variable results.
  • Peptides according to embodiments of the invention may be administered to patients showing symptoms of PTSD.
  • peptides according to embodiments of the invention may be administered to a patient who has undergone a traumatic event.
  • the traumatic event is abuse, domestic violence, violent crime, rape, fire, natural disaster, combat, vehicular accident, medical emergency, death of friend or relative and terror.
  • None limiting examples of subjects who may be treated according to the principles of the present invention include a combat soldier, a firefighter, a law-enforcement officer, a police officer, a medical practitioner or an emergency medical responder.
  • a subject at risk of PTSD is a subject who has scored an above average score on a trauma history questionnaire.
  • peptides according to embodiments of the invention are administered to a subject who is at risk of experiencing a traumatic event. Accordingly, peptides may be administered any time before or after experiencing a traumatic event or before or after reconsolidation treatment.
  • peptides according to embodiments of the invention are administered after a subject experiences a traumatic event.
  • peptides according to embodiments of the invention are administered up to 24 hours (e.g., between 1 minute and 1 day) following the traumatic event.
  • peptides according to embodiments of the invention are administered between 24 hours and one week following the traumatic event.
  • peptides according to embodiments of the invention are administered between 1 week and 1 month following the traumatic event.
  • a subject who has experienced a traumatic event may recall and actively consolidate memory of a traumatic event in a process called "reconsolidation," and may be simultaneously treated with a peptide according to an embodiment of the invention.
  • the subject may be treated with a peptide according to an embodiment of the invention up to 24 hours prior to reconsolidation.
  • the subject may be treated with a peptide according to an embodiment of the invention between 1 minute and 6 hours or between 6 and 24 hours subsequent to reconsolidation.
  • a "therapeutically effective amount" of the peptide is that amount of peptide which is sufficient to provide a beneficial effect to the subject to which the peptide is administered. More specifically, a therapeutically effective amount means an amount of the peptide effective to prevent, alleviate or ameliorate tissue damage or symptoms of a disease of the subject being treated.
  • peptide 1 Ac-RRQRYTPFPLGFE-Lys(Biotin)-NH2-OH (SEQ ID NO: 9), hereinafter referred to as peptide 1
  • peptide 2 As a control peptide, a peptide derived from an E helix site of ephrinA4 having the sequence Ac-RRWSGYEACTAEG-Lys(Biotin)-NH2-OH (SEQ ID NO: 10), hereinafter referred to as peptide 2, was manufactured by the same manufacturer using similar procedures. Both peptides were biotinylated via a lysine side chain for detection in models. Purity of both peptides was determined to be greater than 95% using high-performance liquid chromatography using ultraviolet detection at 214 nanometers.
  • a pull-down assay was performed to test the affinity of peptide 1 and peptide 2 to
  • EphA4 receptor Homogenized rat brain was used as a source for EphA4 receptor.
  • Rat brains were homogenized with Tris (tris(hydroxymethyl)aminomethane) buffer comprising 50 millimolar (mM) tris, 1% NP-40 and 2 mM ethylenediaminetetraacetic acid.
  • Peptides 1 and 2 in amounts of 20 micrograms, were respectively incubated for 1 hour with equal amounts of brain lysate diluyted with 50 mM Tris buffer at room temperature, followed by incubation for 1 hour with 50 microliters of Streptavidin Agarose. The samples were washed with 50 mM Tris buffer. Proteins were then eluted with boiled sample buffer and separated using gel electrophoresis (SDS-PAGE).
  • the blots were then subjected to horseradish peroxide-conjugated anti-mouse or anti-rabbit IgG (1: 1500- Jackson ImmunoResearch Laboratories) in wash buffer for 1 hr at room temperature. Blots were washed with wash buffer for 30 minutes. The blots were subjected to electrochemiluminescence for 1 minute and visualized and quantified using a charge-coupled device camera (XRS; Bio-Rad).
  • XRS charge-coupled device camera
  • Fear conditioning is a procedure in which groups of animals are trained to associate a neutral stimulus, such as a tone, with an aversive event. Subsequently, the neutral stimulus is administered to the groups of animals, and the animals' responses are analyzed. A test group of animals is administered a test agent which may inhibit the long term association in the memory of the animals between the neutral stimulus and the aversive event. If at a point in time about 24 hours after training the animals in the test group respond to the stimulus to a lesser degree than the animals in the control group without having other significant side effects, the test agent is determined to inhibit formation of long term memories. Such an agent may be considered for use in treatment of a disease associated with memory formation, for example PTSD. It is most desirable for an agent used in PTSD to inhibit long term memory formation, but not to inhibit short term memory formation. Short term memory formation was also tested in the current model by testing responses to stimulus 60 minutes after training.
  • LA lateral amygdala
  • rats were housed separately at 22 + 2°C in a 12 hour light/dark cycle, with free access to food and water. Behavioral experiments were approved by the University of Haifa Institutional Committee for animal experiments in accordance with National Institutes of Health guidelines.
  • Rats were habituated to the training chamber and to the injection machine for 2 days for 30 min each day. On the next day the animals were subjected to the fear conditioning protocol. Animals were randomized into three groups: saline control group (6 animals), to which saline was administered; peptide 1 group (9 animals), to which peptide 1 was administered, and peptide 2 group (6 animals) to which peptide 2, a control peptide which does not inhibit EphA4 receptor, was administered.
  • the stylus was removed from the guide cannula and a 28 gauge injection cannula, extending 1.5 mm from the tip of the guide cannula aimed to the LA was carefully placed.
  • the injection cannula was connected via polyethylene (PE20) tubing, back filled with saline with a small air bubble separating the saline from the peptide solution, to a 10 ⁇ Hamilton micro- syringe, driven by a microinjection pump (CMA/100, Carnegie Medicine; or PHD 2000, Harvard Apparatus). Solution was injected at a rate of 0.5 microliter per minute ( ⁇ /min). Total volume injected per amygdala was 0.5 ul. Peptide 1 and Peptide 2 were each dissolved in saline at concentration of 10 ⁇ g/ ⁇ l. Following injection, the injection cannula was left for an additional 1 min before withdrawal to minimize dragging of injected liquid along the injection track.
  • PE20 polyethylene
  • Rat groups were then tested in a different cage, 1 hour after training for short-term memory or 24 hours after training for long-term memory. Three hundred seconds after the start of the testing animals were subjected to 5 tone presentations (40 sec, 5 kHz, 80 dB) with an average inter trial interval of 180 seconds.
  • Freezing was calculated by a video camera placed in the chamber which analyzed movement of animals upon tone presentations. The results were summed and averaged for each group and were expressed in terms of percentage of time of tone presentations that animals were frozen.
  • a fear conditioning in vivo model was performed as in example 3 A, however, no cannula was introduced into the rats.
  • the rats were administered a single dose of 20 ⁇ 1 of a composition having a concentration of 10 ⁇ g/ ⁇ l of peptide 1, or an equivalent amount of saline.
  • a fear memory test was performed 24 hours after the injection.
  • Peptide 1 is effective in block long-term fear conditioning memory, even when administered systemically.
  • Peptide 1 may be a viable agent for treating disease associated with fear-related memory formation, even when administered systemically, for example, subcutaneously.
  • Figure 4A illustrates a molecular model of ephrinA4 binding to EphA4 receptor using the Swiss-Model.
  • the upper panel shows that the ephrinA4 peptide (depicted "pep-ephrinA4") is derived from the GH loop binding domain of ephrinA4.
  • the control peptide (pep-control) is derived from E helix of the ephrinA4.
  • the lower panel shows a molecular model of pep-ephrinA4 peptide bound to EphA4.
  • Protein extracts from the slices were immunoprecpitated with anti-EphA4 antibody and subjected to Western blot with anti-EphA4 or anti-phosphotyrosine antibodies.
  • the upper panel shows that pep-ephrinA4 abolished ephrinA4-induced EphA4 receptor tyrosine phosphorylation.
  • the lower panel shows the EphA4 protein level in immunoprecipitates.
  • EphA4 in the control Ringer's group is not significantly different from the ephrinA4+pep-ephrinA4 group (p>0.6). This indicates that Pep-ephrinA4 inhibits ephrinA4-induced EphA4 tyrosine phosphorylation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à des peptides d'inhibiteur du récepteur Eph A et, en particulier, à des peptides d'inhibiteur du récepteur Eph A4. Les peptides comprennent une séquence dérivée de la boucle G-H de l'éphrine A4. En outre, la présente invention se rapporte à des compositions pharmaceutiques qui comprennent lesdits peptides, et à leurs utilisations pour traiter, améliorer ou prévenir des maladies associées à la formation de souvenirs.
PCT/IL2014/050359 2013-04-18 2014-04-13 Inhibiteurs du récepteur eph-a et utilisations de ces derniers WO2014170900A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP14785453.3A EP2986627B1 (fr) 2013-04-18 2014-04-13 Inhibiteurs du récepteur eph-a et utilisations de ces derniers
US14/785,456 US9765116B2 (en) 2013-04-18 2014-04-13 Inhibitors of the Eph-A receptor and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361813195P 2013-04-18 2013-04-18
US61/813,195 2013-04-18

Publications (1)

Publication Number Publication Date
WO2014170900A1 true WO2014170900A1 (fr) 2014-10-23

Family

ID=51730893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2014/050359 WO2014170900A1 (fr) 2013-04-18 2014-04-13 Inhibiteurs du récepteur eph-a et utilisations de ces derniers

Country Status (3)

Country Link
US (1) US9765116B2 (fr)
EP (1) EP2986627B1 (fr)
WO (1) WO2014170900A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182415A1 (fr) * 2020-06-17 2021-12-23 Maghsoud Dariani Methodes et compositions pour traiter une lesion cerebrale traumatique legere, un trouble de stress post-traumatique et une lesion cerebrale traumatique legere avec trouble de stress post-traumatiqu

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity
WO2010141974A1 (fr) * 2009-06-10 2010-12-16 The University Of Melbourne Applications thérapeutiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050049194A1 (en) * 2001-11-09 2005-03-03 Jonas Frisen Use of ephrins and related molecules to regulate cellular proliferation
AU2011360938B2 (en) * 2010-12-08 2016-07-28 Abbvie Stemcentrx Llc Novel modulators and methods of use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683202B1 (fr) 1985-03-28 1990-11-27 Cetus Corp
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity
WO2010141974A1 (fr) * 2009-06-10 2010-12-16 The University Of Melbourne Applications thérapeutiques

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Basic and Clinical Immunology", 1994, APPLETON & LANGE
"Cell Biology: A Laboratory Handbook", vol. I-III, 1994
"Current Protocols in Immunology", vol. I-III, 1994
"Genome Analysis: A Laboratory Manual Series", vol. 1-4, 1998, COLD SPRING HARBOR LABORATORY PRESS
"Protocols in Molecular Biology", vol. I-III, 1994
"Strategies for Protein Purification and Characterization - A Laboratory Course Manual", 1996, CSHL PRESS
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1989, JOHN WILEY AND SONS
DATABASE PROTEIN [online] 2 July 1998 (1998-07-02), CERRETTI D. P. ET AL.: "EPHRIN-A4 PRECURSOR [MUS MUSCULUS]", XP055290818, retrieved from NCBI Database accession no. NP_031936 *
FRESHNEY: "Culture of Animal Cells - A Manual of Basic Technique", 1994, WILEY-LISS
KOOLPE, M. ET AL.: "An ephrin mimetic peptide that selectively targets the EphA2 receptor.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 49, 6 December 2002 (2002-12-06), pages 46974 - 46979, XP002309754 *
PERBAL: "A Practical Guide to Molecular Cloning", 1988, JOHN WILEY & SONS
SAVELIEVA, K. V. ET AL.: "Learning and memory impairment in Eph receptor A6 knockout mice.", NEUROSCIENCE LETTERS, vol. 438, no. 2, 31 December 2004 (2004-12-31), pages 205 - 209, XP022681937 *
See also references of EP2986627A4
WATSON ET AL.: "Scientific American Books", article "Recombinant DNA"

Also Published As

Publication number Publication date
US20160083428A1 (en) 2016-03-24
US9765116B2 (en) 2017-09-19
EP2986627B1 (fr) 2019-04-10
EP2986627A4 (fr) 2016-11-30
EP2986627A1 (fr) 2016-02-24

Similar Documents

Publication Publication Date Title
US5891849A (en) Methods and formulations for preventing progression of neuropathic pain
DK2120987T3 (en) Treatment of stroke and other diseases without inhibiting N-type calcium channels
CA2224795C (fr) Compositions et formulations permettant de produire une analgesie et d'inhiber la progression de troubles lies a des douleurs neuropathiques
US20110195909A1 (en) Novel x-conotoxin peptides (-ii)
KR20240025721A (ko) 노화와 연관된 질환을 치료하기 위한 방법 및 조성물
KR101993937B1 (ko) 염증 억제용 펩티드
JP5208135B2 (ja) 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物
EP0751954B1 (fr) Composition et methode anti-inflammatoires dans lesquelles de la des-tyr dynorphine et des analogues sont utilises
EP3160489B9 (fr) Inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de la cystite
WO2016207413A1 (fr) Nouvelle utilisation d'inhibiteurs peptidiques à perméabilité cellulaire de la voie de transduction du signal jnk pour le traitement de troubles cognitifs légers
WO2022117116A1 (fr) PEPTIDE INIBITEUR Α9α10 NACHR ET SON UTILISATION
JP2013535965A (ja) 鎮痛作用とａｓｉｃチャンネルを阻害する新規ペプチド
EP2986627B1 (fr) Inhibiteurs du récepteur eph-a et utilisations de ces derniers
JP4944611B2 (ja) ニューロンの成長を調節する化合物およびそれらの使用
JP6735676B2 (ja) Ｃ−ｆｏｓの選択的インヒビターおよびその抗増殖特性
US10561706B2 (en) Isolated polypeptide and compositions comprising same
EP3464325A1 (fr) Peptides inhibiteurs à squelette cyclisé du facteur de différenciation myéloïde 88 (myd88)
US20180186834A1 (en) Novel peptide and use thereof
EP3887390A1 (fr) Agents de liaison à dpep-1 et leurs méthodes d'utilisation
US20230203107A1 (en) Peptide for treating sepsis derived from rv3364c protein of mycobacterium tuberculosis
US20240083948A1 (en) Modified peptides and associated methods of use
US20210238229A1 (en) Peptide for disease treatment
WO2016038608A1 (fr) Peptides dérivés du récepteur de l'angiotensine et leur utilisation
US8629242B2 (en) Methods of inhibiting calcineurin with ApoE analogs
WO2023238127A1 (fr) Peptides cycliques présentant une affinité élevée à l'ubiquitine et leurs procédés d'utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14785453

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 241896

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14785456

Country of ref document: US

Ref document number: 2014785453

Country of ref document: EP